The Global Radiopharmaceuticals Market is projected to reach USD 7,225.6 million by 2024, growing at a compound annual growth rate (CAGR) of 3.5% until 2033. The market's growth is attributed to rising interest in nuclear medicine for cancer and cardiovascular diagnostics, advancements in radiopharmaceutical technologies, and an increase in chronic conditions. In the US, the radiopharmaceuticals market is expected to grow from USD 2,278.8 million in 2024 to USD 3,049.4 million by 2033, driven by the use of SPECT and PET imaging. The competitive landscape is characterized by companies like Bayer AG, Bracco Imaging, Cardinal Health, and Novartis AG, focusing on R&D and strategic partnerships. Diagnostic radiopharmaceuticals are dominating the market, especially for cancer and cardiovascular disease detection. North America is anticipated to hold a 37.5% market share in 2024, benefiting from a strong healthcare infrastructure and favorable regulatory conditions. Additional market insights include projections for various healthcare sectors, such as kidney dialysis, addiction rehabilitation, and in vitro diagnostics, highlighting significant growth opportunities across multiple healthcare domains.
Mon, 20 Jan 2025 15:32:41 GMT | GlobeNewswire